Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.

Literature DB >> 29611077

Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.

Stefano Fiorucci¹, Michele Biagioli², Eleonora Distrutti³.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2018 PMID： 29611077 DOI： 10.1007/s10620-018-5039-y

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

13 in total

1. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Authors: Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer
Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682

2. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

Authors: Aurelien Amiot; Jean-Charles Grimaud; Laurent Peyrin-Biroulet; Jerome Filippi; Benjamin Pariente; Xavier Roblin; Anthony Buisson; Carmen Stefanescu; Caroline Trang-Poisson; Romain Altwegg; Philippe Marteau; Thibaud Vaysse; Anne Bourrier; Stephane Nancey; David Laharie; Matthieu Allez; Guillaume Savoye; Jacques Moreau; Charlotte Gagniere; Lucine Vuitton; Stephanie Viennot; Alexandre Aubourg; Anne-Laure Pelletier; Guillaume Bouguen; Vered Abitbol; Yoram Bouhnik
Journal: Clin Gastroenterol Hepatol Date: 2016-02-22 Impact factor: 11.382

3. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

Authors: A Amiot; M Serrero; L Peyrin-Biroulet; J Filippi; B Pariente; X Roblin; A Buisson; C Stefanescu; C Trang-Poisson; R Altwegg; P Marteau; T Vaysse; A Bourrier; S Nancey; D Laharie; M Allez; G Savoye; J Moreau; L Vuitton; S Viennot; A Aubourg; A-L Pelletier; G Bouguen; V Abitbol; C Gagniere; Y Bouhnik
Journal: Aliment Pharmacol Ther Date: 2017-06-08 Impact factor: 8.171

4. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

Authors: A Stallmach; C Langbein; R Atreya; T Bruns; A Dignass; K Ende; J Hampe; F Hartmann; M F Neurath; J Maul; J C Preiss; R Schmelz; B Siegmund; H Schulze; N Teich; U von Arnim; D C Baumgart; C Schmidt
Journal: Aliment Pharmacol Ther Date: 2016-10-07 Impact factor: 8.171

5. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.

Authors: Elisa K Boden; Donna M Shows; Michael V Chiorean; James D Lord
Journal: Dig Dis Sci Date: 2018-01-25 Impact factor: 3.199

6. Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245

7. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.

Authors: D C Baumgart; B Bokemeyer; A Drabik; A Stallmach; S Schreiber
Journal: Aliment Pharmacol Ther Date: 2016-04-01 Impact factor: 8.171

8. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Authors: Maria Rosario; Jonathan L French; Nathanael L Dirks; Serap Sankoh; Asit Parikh; Huyuan Yang; Silvio Danese; Jean-Frédéric Colombel; Michael Smyth; William J Sandborn; Brian G Feagan; Walter Reinisch; Bruce E Sands; Miguel Sans; Irving Fox
Journal: J Crohns Colitis Date: 2017-08-01 Impact factor: 9.071

Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.

1. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

2. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

3. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

4. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

5. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.

6. Vedolizumab as induction and maintenance therapy for ulcerative colitis.

7. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.

8. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

9. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.

Review 10. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.

Review 1. Bile Acids Activated Receptors Regulate Innate Immunity.

2. Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation.